



Amend B / # 12
7.2
RECEIVED
JUL 11 2002
TECH CENTER 1800/2800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gyuris et al.

Serial No: 09/764,918

Filed: January 18, 2001

For: Chimeric Polypeptides of Serum
Albumin and Uses Related Thereto

Attorney Docket No. GPCI-P02-109

Art Unit: 1642

Examiner: Natalie A. Davis

CERTIFICATE OF FACSIMILE UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231 on the date indicated below:

July 2, 2002

Date of Signature
and of Mail Deposit

Joanne Ryan
Joanne Ryan

Assistant Commissioner of Patents
Washington, D.C. 20231

REPLY UNDER 37 C.F.R. 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed April 2, 2002, in connection with the above application. Please enter the following amendments:

In the specification:

Please replace the 1st full paragraph of page 4 with the following paragraph:

B1

The invention also comprises a pharmaceutical composition comprising a chimeric polypeptide as described above, and methods for treating a disease in an organism by administering an effective dose of such a pharmaceutical composition to the organism. In a currently preferred embodiment, a chimeric polypeptide according to the invention comprises a fragment of an angiogenesis-inhibiting protein, such as angiostatin or endostatin, as the heterologous peptide sequence and is capable of inhibiting angiogenesis. For example, a peptide fragment that inhibits angiogenesis and which may be incorporated into a subject polypeptide is RGD (Arg-Gly-Asp), or a sequence which includes the sequence RGD (e.g., VRGDF, SEQ ID



1642

RECEIVED

JUL 11 2002

PTO/SB/17 (11-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	09/764918
Filing Date	January 18, 2001
First Named Inventor	Jeno Gyuris
Examiner Name	N. Davis
Group Art Unit	1642
Attorney Docket No.	GPCI-P02-109

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account

Deposit Account Number: 18-1945

Deposit Account Name: Ropes & Gray

The Commissioner is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)				3. ADDITIONAL FEES	
Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	180.00
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37CFR 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other fee (specify)					
*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$)	180.00

FEE CALCULATION			
1. BASIC FILING FEE			
Large Entity		Small Entity	
Fee Code	Fee (\$)	Fee Code	Fee (\$)
101	740	201	370
106	330	206	165
107	510	207	255
108	740	208	370
114	160	214	80
SUBTOTAL (1) (\$)		0.00	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Extra Claims Fee from below Fee Paid

Total Claims: 20** = 20 x 10 = 200

Independent Claims: 3** = 3 x 10 = 30

Multiple Dependent: 10 = 10 x 10 = 100

Large Entity		Small Entity	
Fee Code	Fee (\$)	Fee Code	Fee (\$)
103	18	203	9
102	84	202	42
104	280	204	140
109	84	209	42
110	18	210	9
SUBTOTAL (2) (\$)		0.00	

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY

Name (Print/Type)	Yu Lu	Registration No. (Attorney/Agent)	50,306	Complete (if applicable)	Telephone	(617) 951-7268
Signature				Date	July 2, 2002	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 7/02/02 Signature: Joanne Ryan (Joanne Ryan)